NCT06755762 Using a 3D Culture Model for Circulating Tumor Cells Combined With Molecular Bioassays in Patients With HNSCC Cancer
| NCT ID | NCT06755762 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chang Gung Memorial Hospital |
| Condition | Circulating Tumor Cell |
| Study Type | OBSERVATIONAL |
| Enrollment | 88 participants |
| Start Date | 2024-08-01 |
| Primary Completion | 2025-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 88 participants in total. It began in 2024-08-01 with a primary completion date of 2025-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cancer has been a significant cause of human death in the recent two decades, although detection, diagnosis, and cancer treatments improved and evolved rapidly. Till now, the reasons why some cancer recurs and others do not remain unclear. Since 2004, circulating tumor cell (CTC) has been well-recognized that CTCs in the circulatory system are associated with cancer metastasis. The fundamental studies of CTCs hold tremendous potentials for probing the biological insights on the molecular mechanisms underlying cancer metastasis, cancer-related gene mutation, or biomarker discovery. However, the low purity (one of the natural limitations) of isolated samples often hampered CTC-directed studies' utility. For that, investigators used a well-established device (ODEP, optically-induced-dielectrophoresis) to isolate viable and high-purity CTCs for the following investigations. Investigators team developed a protocol in the past months and succeeded in cultivating CTCs (near 100%) for further drug tests and had a technology platform of organoid culture system developing in 2020. The preliminary results of the experiments showed a promising combination. That urges investigators to propose a 3-year project investigating CTC culture in the organoid system to look at (1) the behavior of CTCs in organ cell background (organoid), (2) the influences of different background cells, (3) the different in-vitro (or in-organoid) response of CTCs to specific drugs (pembrolizumab, nivolumab, cetuximab, cisplatin, 5-FU, taxanes) of head and neck squamous cell carcinoma. In the meantime, investigators will look at the genomic alterations of those CTCs growing fast and well in the organoid systems to find possible precipitating metastasis genes at a scale of cell (CTC) level. Investigators believe that the project is doable and possibly help human cancer control and understanding.
Eligibility Criteria
Inclusion Criteria: 1. age ≥ 18 2. agree with blood drawing and follow the procedure of the trial a.health participants:without cancer over 5 yaers b.cancer participants:pathology: metastatic HNSCC patients Exclusion Criteria: 1. health participants:with serious illness 2. cancer participants:none
Contact & Investigator
Chia-Hsun Hsieh, PhD
STUDY CHAIR
Division of Oncology, Chang Gung Memorial Hospital
Frequently Asked Questions
Who can join the NCT06755762 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Circulating Tumor Cell. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06755762 currently recruiting?
Yes, NCT06755762 is actively recruiting participants. Contact the research team at wisdom5000@gmail.com for enrollment information.
Where is the NCT06755762 trial being conducted?
This trial is being conducted at Taoyuan, Taiwan.
Who is sponsoring the NCT06755762 clinical trial?
NCT06755762 is sponsored by Chang Gung Memorial Hospital. The principal investigator is Chia-Hsun Hsieh, PhD at Division of Oncology, Chang Gung Memorial Hospital. The trial plans to enroll 88 participants.